The pooled prevalence of the mental problems of Chinese medical staff during the COVID-19 outbreak: A meta-analysis

Hu, Na; Deng, Hang; Yang, Han‐Xue; Wang, Chundi; Cui, Yonghua; Chen, Jingxu; Wang, Yanyu; He, Sushuang; Chai, Jiabao; Liu, Fuquan; Zhang, Pan; Xiao, Xue; Y, Li

doi:10.1016/j.jad.2022.02.045

Cited by 20 publications

(13 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Explanatory factors of the high heterogeneity and moderators were roughly similar to those in the general population such as different scales and cutoffs (e.g., [ 33 ]), non-random sampling or sample (size) differences (e.g., [ 34 , 36 ]), region of study (e.g., [ 74 , 135 ]), and quality or risk of bias scores of studies [ 9 , 42 ]. Similarly, prevalence rates were higher in studies with larger proportions of female versus male workers, medical versus non-medical professionals, frontline versus non-frontline workers, and nurses versus doctors (e.g., [ 27 , 41 , 56 , 97 , 102 , 105 , 107 , 123 ]). Prevalence rates of above cut-off PTSD level were related to COVID-19 mortality rate [ 60 ] and inconsistently to age (e.g., higher in older [ 61 , 143 ] or in younger health professionals [ 138 ]).…”

Section: Resultsmentioning

confidence: 99%

COVID-19 and common mental health symptoms in the early phase of the pandemic: An umbrella review of the evidence

et al. 2023

View full text Add to dashboard Cite

Background There remains uncertainty about the impact of the Coronavirus Disease 2019 (COVID-19) pandemic on mental health. This umbrella review provides a comprehensive overview of the association between the pandemic and common mental disorders. We qualitatively summarized evidence from reviews with meta-analyses of individual study-data in the general population, healthcare workers, and specific at-risk populations. Methods and findings A systematic search was carried out in 5 databases for peer-reviewed systematic reviews with meta-analyses of prevalence of depression, anxiety, and post-traumatic stress disorder (PTSD) symptoms during the pandemic published between December 31, 2019 until August 12, 2022. We identified 123 reviews of which 7 provided standardized mean differences (SMDs) either from longitudinal pre- to during pandemic study-data or from cross-sectional study-data compared to matched pre-pandemic data. Methodological quality rated with the Assessment of Multiple Systematic Reviews checklist scores (AMSTAR 2) instrument was generally low to moderate. Small but significant increases of depression, anxiety, and/or general mental health symptoms were reported in the general population, in people with preexisting physical health conditions, and in children (3 reviews; SMDs ranged from 0.11 to 0.28). Mental health and depression symptoms significantly increased during periods of social restrictions (1 review; SMDs of 0.41 and 0.83, respectively) but anxiety symptoms did not (SMD: 0.26). Increases of depression symptoms were generally larger and longer-lasting during the pandemic (3 reviews; SMDs depression ranged from 0.16 to 0.23) than those of anxiety (2 reviews: SMDs 0.12 and 0.18). Females showed a significantly larger increase in anxiety symptoms than males (1 review: SMD 0.15). In healthcare workers, people with preexisting mental disorders, any patient group, children and adolescents, and in students, no significant differences from pre- to during pandemic were found (2 reviews; SMD’s ranging from −0.16 to 0.48). In 116 reviews pooled cross-sectional prevalence rates of depression, anxiety, and PTSD symptoms ranged from 9% to 48% across populations. Although heterogeneity between studies was high and largely unexplained, assessment tools and cut-offs used, age, sex or gender, and COVID-19 exposure factors were found to be moderators in some reviews. The major limitations are the inability to quantify and explain the high heterogeneity across reviews included and the shortage of within-person data from multiple longitudinal studies. Conclusions A small but consistent deterioration of mental health and particularly depression during early pandemic and during social restrictions has been found in the general population and in people with chronic somatic disorders. Also, associations between mental health and the pandemic were stronger in females and younger age groups than in others. Explanatory individual-level, COVID-19 exposure, and time-course factors were scarce and showed inconsistencies across reviews. For policy and research, repeated assessments of mental health in population panels including vulnerable individuals are recommended to respond to current and future health crises.

show abstract

Section: Resultsmentioning

confidence: 99%

COVID-19 and common mental health symptoms in the early phase of the pandemic: An umbrella review of the evidence

et al. 2023

View full text Add to dashboard Cite

show abstract

“…During this COVID-19 pandemic, research demonstrated an increased level of mental health problems, e.g., anxiety, depression and somatization of people across population subgroups, especially in nonclinical population ( Dragioti et al., 2021 ; Hu et al., 2022 ; Zhang et al., 2022 ). The level of some symptoms, depression and loneliness due to COVID, were raised in nonclinical populations to the extent that nondifferences between clinical and nonclinical subjects were observed ( Rek et al., 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Development and validation of 21-item outcome inventory (OI-21)

Wongpakaran

Kövi

2022

Heliyon

View full text Add to dashboard Cite

“…Beyond fatigue, healthcare workers grapple with psychological challenges. A meta-analysis on mental health revealed that 29% of Chinese medical staff experienced depression, 27% faced anxiety, and 40% encountered sleep problems during the COVID-19 pandemic [5]. Notably, higher depression scores can exacerbate fatigue symptoms and increase the susceptibility to COVID-19 [6,7].…”

Section: Introductionmentioning

confidence: 99%

PFC/M1 activation and excitability: a longitudinal cohort study on fatigue symptoms in healthcare workers post-COVID-19

Han,

Dai,

Liang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Fatigue is one of the most common neurological symptoms reported post coronavirus disease 2019 (COVID-19) infection. In order to establish effective early intervention strategies, more emphasis should be placed on the correlation between fatigue and cortical neurophysiological changes, especially in healthcare workers, who are at a heightened risk of COVID-19 infection. Methods A prospective cohort study was conducted involving 29 COVID-19 medical workers and 24 healthy controls. The assessment included fatigue, sleep and health quality, psychological status, and physical capacity. Functional near-infrared spectroscopy (fNIRS) was employed to detect activation of brain regions. Bilateral primary motor cortex (M1) excitabilities were measured using single- and paired-pulse transcranial magnetic stimulation. Outcomes were assessed at 1, 3, and 6 months into the disease course. Results At 1-month post-COVID-19 infection, 37.9% of patients experienced severe fatigue symptoms, dropping to 10.3% at 3 months. Interestingly, the remarkable decreased activation/excitability of bilateral prefrontal lobe (PFC) and M1 were closely linked to fatigue symptoms after COVID-19. Notably, greater increase in M1 region excitability correlated with more significant fatigue improvement. Re-infected patients exhibited lower levels of brain activation and excitability compared to single-infection patients. Conclusions Both single infection and reinfection of COVID-19 lead to decreased activation and excitability of the PFC and M1. The degree of excitability improvement in the M1 region correlates with a greater recovery in fatigue. Based on these findings, targeted interventions to enhance and regulate the excitability of M1 may represent a novel strategy for COVID-19 early rehabilitation. Trial registration The Ethics Review Committee of Xijing Hospital, No. KY20232051-F-1, registered February 3, 2023. The Chinese Clinical Trial Registry, ChiCTR2300068444, registered February 20, 2023. https://www.chictr.org.cn

show abstract

The pooled prevalence of the mental problems of Chinese medical staff during the COVID-19 outbreak: A meta-analysis

Cited by 20 publications

References 55 publications

COVID-19 and common mental health symptoms in the early phase of the pandemic: An umbrella review of the evidence

COVID-19 and common mental health symptoms in the early phase of the pandemic: An umbrella review of the evidence

Development and validation of 21-item outcome inventory (OI-21)

PFC/M1 activation and excitability: a longitudinal cohort study on fatigue symptoms in healthcare workers post-COVID-19

Contact Info

Product

Resources

About